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Background: Dengue is prevalent in as many as 128 countries with more than 100 million clinical episodes re-
ported annually and four billion people estimated to be at risk. While dengue fever is systematically diagnosed in
large parts of Asia and South America, the disease burden in Africa is less well investigated. This report describes
two consecutive dengue outbreaks in Ouagadougou, Burkina Faso in 2016 and 2017.
Methods: Blood samples of febrile patients received at Schiphra laboratory in Ouagadougou, Burkina Faso, were
screened for dengue infection using SD Bioline Dengue Duo rapid diagnostic test kits (Standard Diagnostics,
Suwon, Republic of Korea).
Results: A total of 1,397 and 1,882 cases were reported by a single laboratory in 2016 and 2017, respectively. Most
cases were at least 15 years of age and the results corroborated reports from WHO indicating the circulation of
three dengue virus serotypes in Burkina Faso.
Conclusion: This study complements data from other, simultaneously conducted surveillance efforts, and indicates
that the dengue disease burden might be underestimated in sub-Saharan African nations. Dengue surveillance
should be enhanced in African settings to determine the burden more accurately, and accelerated efforts towards a
dengue vaccine should be put in place.1. Introduction
Dengue infection is the most common mosquito-transmitted (genus
Aedes) viral disease with more than 100 million annual symptomatic
episodes being reported from as many as 128 countries; approximately
four billion people are estimated to be at risk [1, 2, 3]. Yet, given a
high asymptomatic infection rate, the actual burden of dengue is
potentially significantly higher, with estimates ranging to up to four7 October 2019; Accepted 30 Ju
vier Ltd. This is an open access atimes more [4]. The highest numbers of dengue cases are reported in
South America and Asia [2, 3]. Being an urban disease, it principally
arises in densely populated areas, aided by Aedes aegypti breeding
preferences.
While dengue is in most settings solely diagnosed based on the clin-
ical picture, the disease can be confirmed by a variety of diagnostic
methods including the detection of anti-dengue virus (DENV) antibodies,
non-structural protein 1 (NS1) antigen or DENV-specific nucleic acidne 2020
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tings, is often not executed.
This is particularly the case in many African settings, and even though
dengue cases have been reported in 34 African countries, the epidemi-
ology of the disease in Africa is largely undescribed as a consequence of
limited disease surveillance, low awareness, and poor diagnostic facil-
ities [5]. Only 20 laboratory-confirmed outbreaks were reported from 15
sub-Saharan African countries in the period between 1960 and 2010;
however, an additional 300,000 cases were reported from epidemics in
the Seychelles, Reunion, Djibouti, the Comoros, and Cape Verde [6].
More recently, following improved diagnostics and increased public
awareness, there have been dengue cases and associated deaths reported
in Kenya, Somalia, Tanzania, Mozambique, and Sudan [7].
From August to November 2016, the World Health Organization
(WHO) reported a dengue outbreak in Burkina Faso. From 1,266 sus-
pected cases, there were 1,061 probable cases and 15 deaths [8]. Blood
samples from 61 probable cases were dispatched to the Institut Pasteur in
Dakar, Senegal, for confirmation; 29 (47.5%) were DENV-2 positive by
qRT-PCR [8]. In April 2017, the WHO reported an outbreak in Ivory
Coast [9] which then spread to Burkina Faso on August 6th, 2016. ThisFigure 1. Number and geographic distribution of dengue cases in Ouagadougo
infection outbreak. The average monthly precipitation in cm is plotted in black [14].
population. The majority of cases were reported from the west/south-west of Ouag
phra laboratory.
2outbreak consisted of 9,029 suspected cases, 63.9% (5,773/9,029) of
these were positive by rapid diagnostic test (RDT) and 18 deaths were
reported [10]. Two hundred and forty-one blood samples were subjected
to DENV-PCR at the Centre Muraz (the national viral hemorrhagic fever
reference laboratory, Bobo-Dioulasso) of which 58.5% (141/241) were
positive by PCR. Subtyping of 72 PCR-positive samples revealed 58, 12,
and 2 samples positive for DENV-2, -3, and -1 serotypes, respectively
[10]. At the same time, a surveillance study conducted by Lim et al. in
adjacent areas in Ouagadougou from December 2014 to February 2017
encompassing the WHO reported outbreak of August–November 2016
reported 2,929 fever cases during both outbreak and non-outbreak pe-
riods; 25.3% (740/2,929) were dengue-positive [11]. Seventy-three
percent (540/740) of the dengue-positive cases were
laboratory-confirmed and 27.0% (200/740) were classified as probable
dengue; among these 42.8% (317/740) were confirmed by RT-PCR and
the remainder by paired ELISA [11]. During the outbreak period, DENV-2
predominated [70% (181/258) in samples confirmed by RT-PCR], dur-
ing the non-outbreak period, DENV-3 was mostly observed [65% (28/43)
in samples confirmed by RT-PCR] with a few DENV-1 [12% (5/43) in
samples confirmed by RT-PCR] [11].u (2016–2017). (A) Epidemic curve for the 2016 (red) and 2017 (blue) Dengue
(B/C) Geographic distribution of the number of cases in each sector stratified by
adougou in both outbreaks. The red dot depicts the location of the CMA Schi-
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In collaboration with the Laboratoire D'Analyses Medicales at Centre
Medical avec Antenne Chirurgicale (CMA) Protestant Schiphra in Oua-
gadougou, Burkina Faso, we investigated the dengue outbreaks
(Figure 1) using samples collected at CMA. The suspected dengue cases
originated from either Schiphra hospital or from surrounding healthcare
facilities; all diagnostic samples were received in the CMA laboratory.
Samples used for this investigation originated from routine diagnosis of
patients. Blood samples received at the CMA from febrile patients were
screened for dengue infection using the SD Bioline Dengue Duo RDT
which detects the dengue virus NS1 antigen and dengue IgM/IgG anti-
bodies (Standard Diagnostics, Suwon, Republic of Korea). This test was
found to have an overall sensitivity and specificity of 93.9% and 92.0%,
respectively, in a cohort study conducted in Singapore [12]. A more
recent study conducted in Brazil contrasted those results by attributing
the test satisfactory levels of specificity (88%–96%), yet, lower overall
sensitivity of 46.8% [13]; this test was also used in patient screening in
the surveillance study conducted by Lim et al. [11] in other parts of
Ouagadougou. Plasmodium falciparum malaria was detected by micro-
scopy or using the SD Bioline Malaria Pf RDT (Standard Diagnostics,
Suwon, Republic of Korea). Information on date of birth, sex, address,
and date of disease onset was collected as standard practice. Data were
extracted without personal identifiers; therefore, this study was deemed
to be exempt from ethical review by the Institutional Review Board at the
International Vaccine Institute. Statistically, categorical variables were
compared and tested using the Pearson's Chi-square test with Yates'
continuity correction. A map of Ouagadougou delineating administrative
sectors was created using Adobe Illustrator CC Software (Adobe Systems,
San Jose, CA, USA) to show the location number of the RDT-confirmed
dengue cases per sector during the 2016 and 2017 outbreaks
(Figure 1). All data analyses were performed in Microsoft Excel (Micro-
soft, Redmond, WA, USA) and RStudio (RStudio, Boston, MA, USA).
3. Results
Laboratory logbooks were retrospectively screened to identify prob-
able and confirmed dengue cases; 4,939 and 7,498 records were screened
from 2016 and 2017, respectively. Cases referred to CMA from sur-
rounding healthcare facilities accounted for 65% (8,084/12,437) of
assessed cases. The remaining cases originated from Schiphra hospital.
From September 5 to December 31, 2016, 28.3% (1,397/4,939) of pa-
tients presenting with fever to Schiphra hospital tested positive for
dengue virus. This first dengue outbreak peaked on October 28 with 72
identified cases (Figure 1A). An additional 432 cases had been reported
by the time the outbreak had subsided in early December. The largest
proportion of cases was identified in patients aged 15 years (75.8%;
1,059/1,397), followed by children aged <2 years (13.8%; 193/1,397).
Among the confirmed dengue cases, 49.7% (694/1,397) were male and
95.3% (1,267/1,330) of cases were residents of Ouagadougou; data on
residency was unavailable for 67 cases. Outside of Ouagadougou, the
largest case number was observed in Nioko II (11 cases), a temporary
settlement on the northern border of Ouagadougou which has a popu-
lation of low socioeconomic status.
In 2017, a second outbreak occurred between 10th August and 29th
December with a peak of 57 cases on the 17th October. During this time
period, 25.1% (1,882/7,498) of patients presenting to Schiphra hospital
with fever tested positive for dengue. The beginning of the outbreak
coincided with the end of the rainy season in Burkina Faso which runs
from June to September (Figure 1A) [14]. During both outbreaks, the
majority of cases detected at the CMA laboratory resided in the
west/south-west of Ouagadougou (Figures 1B and 1C). In 2016, the
greatest number of cases originated in sector 17 (227 cases) and sector 19
(152 cases) (Figure 1B). In 2017, the greatest number of cases originated3in the south-west and central regions of the city, and the highest number
of cases was again reported in sector 17 (449) (Figure 1C).
Blood samples from febrile patients in 2016 were also assessed for
P. falciparummalaria; 5.9% of the patients (292/4,939) were positive for
P. falciparum. Co-infection of dengue infection and malaria was identified
in 1.4% (39/2,762) of cases; however, dengue infection andmalaria were
negatively associated (p < 0.01).
4. Discussion
Despite the samples from this study originating from a single labo-
ratory, we identified a higher number of dengue cases than those esti-
mated by the WHO and those identified during the outbreak in the health
facility-based surveillance study [11]; hence, results presented here
complement these data. Results shown managed to capture an acute
outbreak that differs from the research study [11], which conducted
fever-based community surveillance. The major differences are that only
RDT results were used to confirm dengue cases and no convalescent sera
and confirmatory testing by RT-PCR had been executed. When adding up
the numbers from the WHO report, the Lim et al. [11] study and the
results shown here, the number of cases officially reported seem to
significantly underestimate the magnitude of the outbreaks. Lim and
colleagues’ study further highlighted the importance of dengue RDTs
usage in routine care to address the issue of under-diagnosis as well as
underreporting in the surveillance system [11].
We observed that the peak number of cases followed the rainy season
in 2016 and 2017; such a seasonal observation has been observed pre-
viously [15, 17]. The difference in reporting numbers is also in line with
the fact that dengue fever is potentially not sufficiently recognized and
reported in Africa due to a variety of reasons, i.e. concomitant diseases
exhibiting similar symptoms, low awareness of clinicians and nurses and,
importantly, the lack of systematic diagnostic testing. Given that the SD
Bioline Dengue Duo RDT has shown varying levels of sensitivity and
specificity [12, 13], the recently reported lower sensitivity of 46.8% in
the Brazilian study [13] suggests that half of the cases actually remain
undetected and the disease burden is potentially even higher. In the study
conducted by Lim et al., RT-PCR was used as confirmatory testing and
subtyping (i.e. not performed on a random sample subset, but mainly on
likely positive samples) [11]. Therefore, the study was not designed to
allow a comparison of performance of different dengue tests [11].
In addition, although the reference laboratory was centrally located,
we observed a disproportionate number of dengue cases originating from
the west/south-west region of Ouagadougou. This might be due to
environmental factors such as increased number of water bodies or, as we
postulate, due to the fact that the number of healthcare facilities in these
areas is lower, and febrile patients preferably refer to the CMA Schiphra
facilities.
Data presented by the WHO and Lim et al. demonstrated the circu-
lation of three different dengue serotypes during the 2017 and 2016
outbreak, respectively; DENV-2 being the most predominant serotype
[10, 11]. Antibodies against one distinct serotype can induce an immu-
nological response against an alternative serotype, but may not
neutralize the virus, which may lead to a phenomenon known as
antibody-dependent enhancement (ADE). ADE may occur following one
or multiple dengue infections, in particular when infected a second time,
resulting in more severe disease manifestations including dengue hem-
orrhagic fever and dengue shock syndrome (severe dengue). More evi-
dence is needed, particularly on the occurrence of severe dengue, but the
simultaneous circulation of three different dengue serotypes may
potentially be one explanation of the relatively high case fatality rate
observed in the recent outbreaks in Burkina Faso. ADE complicates the
development of dengue vaccines, requiring that relevant antibodies
against all serotypes be present and persist. The recently proposed label
change for the recommended target population for Dengvaxia®
J. Im et al. Heliyon 6 (2020) e04389underscores that risk, as vaccination of naïve individuals, during
longer-term follow-up, may be associated with increased susceptibility to
severe dengue following a subsequent dengue virus infection [16]. Given
the potential impact of large dengue outbreaks on healthcare systems, it
may be important to consider dengue vaccines as part of an integrated
program of dengue control in Burkina Faso.
Dengue fever, unlike P. falciparum malaria, is observed principally in
densely populated areas. Aedes aegypti prefers to breed in receptacles that
collect water including car tires, ponds and water storage jars. Mosquitos
of the Anopheles genus associated with transmitting malaria, are not
typically found in urban settlements, which generally lead to a lower risk
of malaria in cities in comparison to more rural locations. Furthermore,
the blood feeding behaviour of the two mosquitos differs substantially.
Anopheles species feeds from dusk till dawn, while A. aegypti predomi-
nantly feeds during daylight [17]. The characteristics of these vectors are
consistent with the negative association observed between malaria and
dengue.
The study has limitations. First, we only obtained cases from a single
laboratory in Ouagadougou, therefore, we are unable to account for cases
reported at other healthcare facilities. This limitationmay account for the
higher number of cases in the west/south-western areas of the city as the
number of healthcare facilities is potentially lower than in the more
central parts of the city. Therefore, case numbers may have been biased
by referral patterns or differences in healthcare-seeking behaviour.
However, there are very few laboratories in the city and the availability
of a low-cost RDT for dengue at CMA resulted in >65% of patients being
referred from across the city. Second, RDT results were not further
confirmed by anti-DENV IgM capture ELISA or PCR, which may result in
a number of false positives, leading to elevated case numbers. However,
such confirmatory testing was performed in the Lim et. al study [11].
5. Conclusions
Improved surveillance and the routine use of an RDT resulted in the
detection of outbreaks with increased dengue case numbers in Burkina
Faso. These cases were detected in addition to a study conducted by
another group at the same time, indicating that the burden of dengue
fever is potentially higher than assumed and that clinical case definition
for dengue is insufficient for dengue diagnosis. The comparison of results
from several sources shows that adequate surveillance and epidemio-
logical studies are paramount to enable the scientific community to
create a situational awareness for this disease, which is severely under-
recognized in Africa. Therefore, more resources should be invested into
dengue surveillance in sub-Saharan Africa to ensure that high risk areas
and high-risk populations are identified to support vaccine introduction
rapidly upon the availability of such knowledge.
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